Lyme disease remains the most common arthropod-bome infection in the United States. The causative agent of the disease was recognized as a spirochete (8, 12, 49) and described as a new Borrelia species (29) . The spirochete, Borrelia burgdorferi, is transmitted following the bite of an infected ixodid tick (12) . In humans, Lyme disease is a multisystem illness that primarily affects the skin, nervous system, heart, and joints (48) .
Considerable effort has been invested in the development of a Lyme disease vaccine. The feasibility of vaccination as a method for the prevention of Lyme disease was evident when hamsters vaccinated with killed whole-cell B. burgdorferi were protected against challenge with a virulent homologous strain (27) . Subsequent research has been directed towards the development of a Lyme disease vaccine with other animal models and has focused on the identification of B. burgdorferi immunoprotective antigens (1, 7, 14, 36, 37, 41, 42, 51) .
A sizeable amount of information has been published pertaining to outer surface protein A (OspA), which has an apparent molecular mass of 31 kDa, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and its effectiveness in eliciting protective immunity. In active immunization studies, vaccination with recombinant OspA in Freund's adjuvant and from strain N40 was reported to protect immunocompetent mice from challenge with strain N40 (18, 19) . In contrast, recombinant OspA in Al(OH)3 and derived from B. burgdorferi PKo did not protect gerbils from infection with strain PKo (37) . Also, posttranslational lipid attachment was found to be a critical determinant for OspA immunogenicity (17) .
However, immunological heterogeneity (6, 20, 55) and molecular heterogeneity (30, 34, 57) (11, 31, 36, 43, 44, 52, 54) . In addition, antibodies against OspA are developed late in the course of disease in tick-infected humans (3, 33, 53, 56) .
The selection of antigenic variants (or escape variants) of B. burgdorferi induced by antibodies was recently reported (15, 16, 39) . In each of these reports, monoclonal antibodies (MAbs) or polyclonal antisera were used to inhibit the growth of wild-type B. burgdorferi and select for antibodyresistant escape variants or mutants. Of the four classes of antibody-resistant mutants described by Sadziene et al. (39) , class I mutants lacked OspA and OspB and the linear plasmid that encodes them, while class II mutants had truncated OspA and/or OspB proteins. Neither the animal infectivity of the class I mutants nor the use of these antibody-resistant mutants of B. burgdorferi in active immunization studies has been reported. An OspB mutant of B. burgdorferi Sh.2 was recently shown to have reduced invasiveness in vitro and reduced infectivity in scid/scid mice (38) .
In this paper, we describe a mutant of virulent B. burgdorferi apparently selected for by long-term storage at 5°C and lacking OspA and OspB. We describe the immunogenicity of the mutant in hamsters. Also, we report studies to determine whether vaccination with this mutant confers protection against infection in hamsters.
MATERIALS AND METHODS
Strains and culture conditions. Borreliae were cultured in Barbour-Stoenner-Kelly (BSK) medium (2) with minor modifications (9) at 30°C. The virulence of wild-type B. burgdorferi 297 (designated hereafter as virulent wild-type 297), a human spinal fluid isolate from Connecticut (49), was maintained by periodic passage through golden Syrian hamsters (28) . Borreliae were recovered from the bladder, spleen, heart, or blood of animals infected with this organism. Avirulent 297 has been maintained in continuous in vitro culture since 1983 and is noninfectious for hamsters injected with 108 cells. Mutant 297 was originally isolated from the heart tissue of a hamster that had been experimentally infected with virulent wild-type 297. The culture tube had been placed at 5°C and stored for 6 months, at which time the culture was subcultured to fresh medium and grown at 30°C. Subcultures were examined for protein content and DNA plasmid profile (see below). Cultures were cloned by limiting dilution (4) .
Growth curves were determined from triplicate cultures for virulent wild-type 297, avirulent 297, and mutant 297. Inocula for growth curve studies consisted of 5 x 106 early-logarithmic-phase cells per 5 ml of medium, yielding a final cell concentration of 1 x 106 cells per ml. At designated time intervals, 0.1 ml of culture was removed from each tube, and live motile spirochetes were counted in a PetroffHausser chamber by dark-field microscopy.
DNA characterization. In situ-lysed DNA samples from each variant were examined by contour-clamped homogeneous electric field pulsed-field gel electrophoresis (CHEF PFGE) as described previously (24) . Lambda phage DNA concatamers (FMC BioProducts, Rockland, Maine) and a 5-kb DNA ladder (Bio-Rad Laboratories, Hercules, Calif.) were used as DNA size standards. The DNA was transferred from the agarose gels to a membrane support (GeneScreen Plus; NEN Research Products, Boston, Mass.) by the method of Southern (47) .
The probe for the ospAB locus was prepared by polymerase chain reaction amplification (21) . Polymerase chain reaction primers represented nucleotides 788 to 812 and 920 to 944 of the ospAB locus sequence (GenBank accession number X14407) (10 Laemmli (32) . Early-log-phase borreliae were harvested by centrifugation at 4°C. The pellet was washed three times with ice-cold 10 mM phosphate-buffered saline (PBS; pH 7.2). The final suspension in 0.0625 M Tris was vortexed, and aliquots were stored at -70°C. The protein content was determined by a detergent-compatible protein assay (Bio-Rad). Linear gradient gels (7.5 to 15.0%) (22) and blood from each animal were cultured. Each hamster organ was placed in 6 ml of BSK medium and homogenized with a Stomacher Lab-Blender (Tekmar Co., Cincinnati, Ohio). After the larger tissue debris was allowed to settle, duplicate 1:10 dilutions of the supernatant were made in BSK medium containing 0.15% agarose (SeaKem LE; FMC). Cultures were examined by dark-field microscopy after 3 weeks of incubation at 30°C.
RESULTS
Characterization of wild-type 297 and mutant 297. A mutant of virulent wild-type B. burgdorferi 297 was apparently selected for by long-term storage at 5°C. In situ-lysed DNA samples from virulent wild-type 297, avirulent 297, and mutant 297 were analyzed by CHEF PFGE to determine plasmid content (Fig. 1A) . Electrophoresis parameters were chosen to optimize the separation of the plasmid bands. The 60-kb plasmid, which corresponds to the linear plasmid that is 49 kb in size in conventional agarose gel electrophoresis (5, 13) and that encodes the OspA and OspB proteins, was absent from the mutant plasmid profile and present in both the virulent wild-type and avirulent plasmid profiles. In addition, a plasmid of approximately 28.4 kb was absent from the mutant and avirulent plasmid profiles. The absence of this plasmid from the profiles may reflect the loss of the DNA from the genome or a DNA rearrangement event. The avirulent 297 plasmid profile also lacked a plasmid doublet at approximately 30 kb and a plasmid at approximately 26.8 kb but gained a plasmid at approximately 25 kb. The addition of the plasmid band in the avirulent 297 plasmid profile may reflect a plasmid rearrangement or, most likely, the loss of DNA from a larger plasmid band.
The loss of the OspA and OspB genes from the mutant genome was verified when a DNA probe specific for the ospAB locus failed to hybridize to the DNA of the mutant (Fig. 1B) . These genes were present on the 60-kb plasmid of both virulent 297 and avirulent 297. The mutant was cloned by limiting dilution. The DNAs from nine in situ-lysed clones were examined by CHEF PFGE. The ospAB plasmid and the 28.4-kb plasmid were also absent from the plasmid profiles of the mutant clones (data not shown).
Growth (Fig. 4) . Data are shown for hamster groups receiving a 100-,ug dose. As expected, prechallenge sera from hamsters vaccinated with mutant 297 lacked antibodies to OspA and Prechallenge hamster sera were collected 14 days after the final vaccination and pooled. Postchallenge sera were collected 14 
DISCUSSION
Mutants and antigenic variants of B. burgdorfen have been described in the literature (11, 15, 16, 39, 43) . A number of these mutants or variants were selected for following incubation of the culture in the presence of antibodies (15, 16, 39 
